Galmed Pharmaceuticals Ltd.

News & Events

Press Releases

In The Media

1. Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

   PR Newswire MAY 27, 2025 8:00 AM EDT
   Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Ex...
   READ ARTICLE

2. Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

   PR Newswire MAY 22, 2025 8:00 AM EDT
   Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update ...
   READ ARTICLE

3. Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

   PR Newswire MAY 13, 2025 8:00 AM EDT
   Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models PR Newswire ...
   READ ARTICLE

4. Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

   PR Newswire APR 28, 2025 8:00 AM EDT
   Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation ...
   READ ARTICLE

5. Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

   PR Newswire APR 17, 2025 8:30 AM EDT
   Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers ...
   READ ARTICLE

6. Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

   PR Newswire APR 15, 2025 8:30 AM EDT
   Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD...
   READ ARTICLE

7. Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

   PR Newswire APR 10, 2025 8:00 AM EDT
   Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced...
   READ ARTICLE

8. Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

   PR Newswire APR 2, 2025 4:10 PM EDT
   Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 3...
   READ ARTICLE

9. Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

   PR Newswire MAR 20, 2025 8:55 AM EDT
   Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, S...
   READ ARTICLE

10. How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

    GlobeNewswire SEP 20, 2024 9:00 AM EDT
    PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary -...
    READ ARTICLE